Grand Challenges Announces Awards for "Innovations for Exceptionally Low-Cost Monoclonal Antibody (mAb) Manufacturing"

The Gates Foundation and LifeArc^* today announced a total of nine grants awarded under the Grand Challenges Innovations for Exceptionally Low-Cost Monoclonal Antibody (mAb) Manufacturing request for proposals. The nine grants were awarded to individuals and teams in four different countries.

This Grand Challenges call sought bold, technically feasible innovations to achieve the long-standing goal of reducing monoclonal antibody (mAb) manufacturing costs to $10 per gram of purified released mAb — a milestone that would make these lifesaving biologics accessible to people in low- and middle-income countries.

Read summaries of all the grants awarded here.

____________________________
* LifeArc is a charity registered with the Charity Commission for England and Wales under registration number 1015243 and a charity registered in Scotland with the Office of the Scottish Charity Regulator under registration number SC037861. LifeArc is also a company limited by guarantee, with company 2698321, incorporated under the laws of England and Wales at 7th Floor, Lynton House 7–12 Tavistock Square, London WC1H 9LT.